, , . , , . ( ) . . D2-.
, . , , , , . , , . , , , . , .
.
, , , , . , , , . , . , 2-4 . , .
.
, . . 1-3%. , . 50% 3000, . , , , , , 6 1 2 . , , (, ), . . , .
.
, , . , . . , , , . QT - .
|
|
- . , , , . 3-4 . ; . , α- , , . , - . QT , .
, , , . .
. . , , , (phenylephrine). β- , . . . 50 / / 2 / /. .
. , . - , , , .
, ( ) . . .
.
.
Hyman SE, Nestler EJ. Molecular foundations of psychiatry. Washington, DC: American Psychiatric Press, 1993.
Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156:286.
Nyberg S, Eriksson B, Oxenstierna G, et al. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999; 156:869.
Tamminga CA. Principles of the pharmacotherapy of schizophrenia. In: Charney DS, Nestler EJ, Bunnery BS, eds. Neurobiology of mental illness. New York: Oxford University Press, 1999.